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Introduction {#sec1}
============

Inherited mutations inactivating the *BRCA2* tumor suppressor gene predispose to cancers of the breast, ovary, pancreas, prostate, and other tissues ([@bib6]). Human BRCA2 protein serves as a custodian of chromosome integrity via the nucleation of multi-protein complexes essential for homologous DNA recombination, replication fork protection, and cell-cycle control (reviewed in [@bib38]). The chromosomal instability characteristic of *BRCA2*-deficient cells has been attributed to loss of these functions, but recent findings show that *BRCA2* deficiency also causes the unscheduled accumulation of RNA-DNA hybrids (R-loops) ([@bib4]) and link R-loop accrual to chromosomal structural aberrations in *BRCA2*-deficient cells ([@bib36]).

The mechanism by which BRCA2 deficiency causes R-loop accumulation remains unclear ([@bib4]). R-loops are normal intermediates during processes like transcription, replication, or DNA repair, but they also occur when RNA polymerase II (RNAPII) stalls at nucleotide lesions that arrest the transcription of DNA templates ([@bib3], [@bib13], [@bib34]). In addition, RNAPII pausing occurs physiologically during an early step in transcription elongation to efficiently manage gene expression patterns that suit cellular requirements ([@bib18]). Most RNAPII-transcribed genes in metazoan cells contain a promoter-proximal pause (PPP) site located ∼20-50 nucleotides downstream of the position where transcription begins ([@bib19], [@bib25], [@bib27]). RNAPII enriched for phosphorylation on Ser5 in its C-terminal domain (CTD) pauses at these sites after the synthesis of a short nascent RNA tract ([@bib5]). RNAPII release from PPP sites is accompanied by the phosphorylation of Ser2 in its CTD by the kinase cyclin T-CDK9 ([@bib11], [@bib21]), empowering the recruitment of a protein complex including RNAPII-associated factor 1 (PAF1) ([@bib9], [@bib42]). In turn, PAF1 recruitment to RNAPII triggers events leading to the ubiquitination of histone H2B on Lys120, a modification that is proposed to open chromatin downstream of the transcription complex to facilitate transcription elongation ([@bib37], [@bib39], [@bib40]). Mounting evidence suggests that RNAPII release from PPP sites is tightly regulated to control mammalian gene expression (reviewed in [@bib1]).

Inactivation of BRCA1, a tumor suppressor protein that is functionally and structurally distinct from BRCA2 but cooperates with it during cellular responses to DNA damage (reviewed in [@bib38]), is also accompanied by unscheduled R-loop accumulation ([@bib14], [@bib43]). A small pool of intracellular BRCA1 interacts with RNAPII ([@bib30], [@bib31]). Conflicting reports variously attribute R-loop formation in BRCA1-deficient cells either to transcription termination sites at the 3′ ends of genes ([@bib14]) via the interaction of BRCA1 with the R-loop resolvase senataxin (SETX) ([@bib33]) or, alternatively, to 5′ PPP sites ([@bib43]) only in certain epithelial cell types through mechanisms that remain unclear. Moreover, whether R-loop accrual following BRCA2 inactivation arises from similar anomalies is not known.

Here, we report an unanticipated role for BRCA2 in the control of transcription elongation at PPP sites through the enhanced recruitment of PAF1 to RNAPII. BRCA2 inactivation by cancer-associated mutations or RNAi-mediated depletion subverts this mechanism, impeding transcription elongation at the PPP sites of actively transcribed genes, accompanied by R-loop accumulation and DNA breakage mediated by the ERCC4 nuclease. By contrast, BRCA1 or SETX depletion causes R-loop accumulation at 3′ transcription termination sites, distinguishing the mechanism mediated by BRCA2. Thus, our work identifies an unrecognized mechanism by which BRCA2 controls transcription elongation and suggests that abnormalities in this process instigate unscheduled R-loop formation and ensuing genomic instability.

Results {#sec2}
=======

BRCA2 Inactivation Triggers R-Loop and DNA Damage Accumulation at PPP Sites {#sec2.1}
---------------------------------------------------------------------------

Nuclear R-loop accumulation detected by the S9.6 antibody specific to R-loop structures ([@bib4], [@bib12]) increases following BRCA2 inactivation by small interfering RNA (siRNA)-mediated depletion in HeLa Kyoto cells ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A) or by bi-allelic cancer-associated truncating mutations (*BRCA2*^*7691insAT*^ ^*/\ 9000insA*^) in the patient-derived EUFA423 fibroblast cell line ([@bib16]) ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}C). By contrast, EUFA423 cells stably complemented with full-length FLAG-tagged BRCA2 (EUFA423 B2) ([@bib15]) show no such abnormality ([Figure 1](#fig1){ref-type="fig"}B).Figure 1BRCA2 Deficiency Leads to R-Loop Formation Accompanied by RNAPII Accumulation at the PPP Sites of Classical Paused Genes(A and B) Immunofluorescence detection of R-loops with S9.6 antibody in HeLa Kyoto cells transfected with either siCtrl (control) or siBRCA2 (A) and BRCA2*-*deficient EUFA423 cells (see [Figure S1](#mmc1){ref-type="supplementary-material"}C) and EUFA423 B2 controls complemented with wild-type BRCA2 (B). HeLa cell transfections were carried out for 72 hr before analysis. Plots show the mean ± SEM from three independent experiments. The two-tailed Student's t test was performed to determine statistical significance between the two groups (^∗∗^p \< 0.01). Scale bars, 10 μm.(C) Schematic diagram of the *ACTB* gene showing primer positions (PPP, In1 or In5, pA, and TES) and exon numbers. DRIP analyses with S9.6 antibody in EUFA423 B2 and EUFA423 (left) and in HeLa Kyoto cells transfected with the indicated siRNA for 72 hr (right) are shown. R-loop digestion by RNase H is shown as a control. Plots depict the mean ± SEM from three independent experiments. The 2-way ANOVA test was performed for all pairs to determine statistical significance. Statistically significant differences are indicated (^∗∗^p \< 0.01, left; ^∗^p \< 0.05, right).(D) Schematic diagram of the *GAPDH* gene, showing primer positions (PPP, In5, and TES) and exon numbers. DRIP analyses were performed and depicted as described in the preceding panels. Statistically significant differences are indicated (^∗^p \< 0.05, left; ^∗∗∗^p \< 0.001, right).(E) Schematic diagram of the *TEFM* gene, showing primer positions (PPP, In2 and TES) and exon numbers. DRIP analyses were performed and depicted as described in the preceding panels. Statistically significant differences are indicated (^∗^p \< 0.05, left; ^∗∗^p \< 0.01, right).

We used S9.6 antibody in DNA-RNA immunoprecipitation (DRIP) analyses ([@bib12]) to survey R-loop formation in genomic DNA across the transcription units of seven actively transcribed genes: *ACTB*, *GAPDH, TEFM*, *MRPL21*, *CALM3*, *RPL13A*, and *VCL* ([@bib14], [@bib29], [@bib44]). We analyzed R-loop formation at the 5′ PPP sites of these genes within 200 nt of their transcription start site (TSS) sequences, as well as at intronic (In) sequences in the gene body or the 3′ sequences associated with transcription-end sites (TESs). In HeLa Kyoto cells depleted of BRCA2, there is a statistically significant increase in R-loop formation at the PPP sites relative to other regions of *ACTB, GAPDH* and *TEFM* ([Figure 1](#fig1){ref-type="fig"}C-E), when compared to cells treated with irrelevant control siRNAs. R-loop formation at the PPP sites of these genes is also increased in BRCA2-deficient EUFA423 cells, in comparison to EUFA423 B2 isogenic controls reconstituted with BRCA2 ([Figures 1](#fig1){ref-type="fig"}C--1E). Similar anomalies occur at the PPP sites of *MRPL21, CALM3, VCL* and *RPL13A* genes in EUFA423 when compared to EUFA423 B2 cells ([Figures 2](#fig2){ref-type="fig"}A--2D). R-loop detection in these experiments is uniformly suppressed by pretreatment with RNase H ([Figures 1](#fig1){ref-type="fig"}C--1E and [2](#fig2){ref-type="fig"}A--2D), an enzyme that digests R-loops ([@bib12]).Figure 2R-Loops Accumulate at the PPP Sites of Multiple Genes in BRCA2-Deficient Cells(A--D) DRIP analysis of *MRPL21* (A), *CALM3* (B), *VCL* (C), and *RPL13A* (D) genes in EUFA423 B2 and EUFA423 cells. R-loop dissolution by RNase H enzyme is shown as a control. Error bars indicate the mean ± SEM from three independent experiments. The 2-way ANOVA test was performed for all pairwise comparisons to determine statistical significance. Statistically significant differences are indicated (^∗∗^p \< 0.01).(E) ChIP analysis with γH2AX antibody of the *GAPDH* gene in EUFA423 B2 and EUFA423 cells, without or with siRNA targeting ERCC4. Fold change relative to EUFA423 B2 is plotted. Error bars indicate the mean ± SEM from three independent experiments. The 2-way ANOVA test was performed for all pairwise comparisons to determine statistical significance. For EUFA423/ERCC4, significance was determined by comparison with EUFA423. Statistically significant differences are indicated (^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001).

Interestingly, R-loop accumulation in the *GAPDH* transcription unit is accompanied by γH2AX formation, a marker for DNA damage ([Figure 2](#fig2){ref-type="fig"}E), most markedly at the PPP site but also at the adjacent intronic region. Depletion of the endonuclease ERCC4 ([@bib32]), which has been implicated in the cleavage of R-loops to DNA breaks ([@bib35]), reduces γH2AX formation ([Figure 2](#fig2){ref-type="fig"}E) without significantly altering R-loop accumulation ([Figure S1](#mmc1){ref-type="supplementary-material"}D). These findings suggest a mechanism wherein R-loop processing by ERCC4 contributes to genomic instability in BRCA2-deficient cells.

By contrast, depletion of BRCA1 enhances R-loops in a significant manner at sequences associated with transcription termination (TES) in *ACTB* ([Figure S2](#mmc1){ref-type="supplementary-material"}A), consistent with a previous report ([@bib14]), but has little effect on R-loop formation at PPP sites, in contrast to another study ([@bib43]). These observations are distinct from the defect that we describe for BRCA2 deficiency. Moreover, we find that BRCA2 depletion increases the accumulation of SETX (a helicase implicated in R-loop resolution during transcription termination; [@bib33]) at PPP sites in *ACTB* and *GAPDH*, as well as in their termination sequences, as detected by chromatin immunoprecipitation (ChIP) ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). This pattern contrasts with the decreased recruitment of SETX to transcription termination sequences observed after BRCA1 depletion ([@bib14]), again suggesting that R-loop formation after BRCA2 depletion occurs via a distinct mechanism.

BRCA2 Inactivation Causes RNAPII Accumulation at PPP Sites {#sec2.2}
----------------------------------------------------------

We next examined the effect of BRCA2 inactivation on the distribution of RNAPII across the *ACTB* and *GAPDH* transcription units using an antibody (N20) ([@bib10]) capable of detecting both the non-phosphorylated and CTD Ser2/Ser5 phosphorylated forms of the enzyme. RNAPII was significantly enriched at PPP sites (as detected by ChIP) in EUFA423 cells carrying bi-allelic *BRCA2* mutations, but not in control EUFA423 B2 cells reconstituted with full-length BRCA2 ([Figure 3](#fig3){ref-type="fig"}A). ChIP using an antibody that selectively binds to the Ser5-phosphorylated form of RNAPII ([@bib7]) reveals a more even distribution across both genes ([Figure 3](#fig3){ref-type="fig"}B), although levels are diminished in *BRCA2*-deficient EUFA423 cells when compared with EUFA423 B2 controls. Collectively, these findings suggest that the release of RNAPII from PPP sites in *ACTB* and *GAPDH* during transcription elongation is delayed, but not stopped.Figure 3RNAPII Accumulates at the PPP Sites of Actively Transcribed Genes(A) ChIP analyses with RNAPII antibody (N20) of the *ACTB* and *GAPDH* genes in EUFA423 B2 and EUFA423 cells. Fold change relative to IgG isotype control is plotted. Plots show the mean ± SEM from three independent experiments. The 2-way ANOVA test was performed to determine statistical significance (^∗^p \< 0.05).(B) ChIP analyses of RNAPII Ser5P in the *ACTB* and *GAPDH* genes in EUFA423 B2 and EUFA423 cells. Data were normalized to input (2%). Plots show the mean ± SEM from three independent experiments; the 2-way ANOVA test was performed as above.

BRCA2 Interacts with RNAPII {#sec2.3}
---------------------------

The unexpected effect of BRCA2 inactivation on RNAPII distribution prompted us to test whether these proteins interact. Indeed, RNAPII immunoprecipitated from HeLa Kyoto cell extracts using the N20 antibody interacts with wild-type BRCA2 ([Figure 4](#fig4){ref-type="fig"}A). EUFA423 cells carry the bi-allelic *BRCA2*^*7691insAT*^ ^*/\ 9000insA*^ truncation mutations, which encode truncated proteins with predicted molecular weights of 278 kDa (*BRCA2*^*7691insAT*^) and 358 kDa (*BRCA2* ^*9000insA*^), while control EUFA423 B2 cells express, in addition, full-length FLAG-tagged BRCA2 protein of 450 kDa. In EUFA423 B2 cell extracts ([Figure 4](#fig4){ref-type="fig"}B, lanes 1--3), RNAPII immunoprecipitated with the N20 antibody interacts with full-length and the BRCA2^*9000insA*^ truncated mutant proteins, but as expected in EUFA423 cell extracts, only with the truncated mutant protein ([Figure 4](#fig4){ref-type="fig"}B, lanes 4--6). Conversely, immunoprecipitation of BRCA2 from EUFA423 B2 ([Figure 4](#fig4){ref-type="fig"}C, lanes 1--3) or EUFA423 ([Figure 4](#fig4){ref-type="fig"}C, lanes 4--6) cell extracts demonstrates that full-length BRCA2, as well as the cancer-associated BRCA2^*9000insA*^ truncated mutant protein, interact with RNAPII detected by an antibody (601) against its CTD ([@bib24]). Reciprocally, this RNAPII antibody also co-immunoprecipitates full-length BRCA2 and the cancer-associated BRCA2^*9000insA*^ truncated mutant protein ([Figure 4](#fig4){ref-type="fig"}D, lanes 1--6). RNAPII that co-immunoprecipitates with full-length or truncated mutant BRCA2 is phosphorylated on Ser2 and Ser5 residues in its CTD ([Figures 4](#fig4){ref-type="fig"}C and 4D). Taken together, our findings demonstrate that RNAPII and BRCA2 interact in human cells and that the cancer-associated BRCA2^*9000insA*^ truncated mutant protein retains this interaction.Figure 4BRCA2 Interacts with RNAPII(A) IP-western analysis showing the interaction between RNAPII and BRCA2 after IP with RNAPII N20 antibody in HeLa Kyoto cell extracts, followed by western blotting with the indicated antibodies.(B) A similar analysis showing the interaction between RNAPII and BRCA2 in EUFA423 B2 and EUFA423 cells. Bars indicate the relative positions of the wild-type or truncated form of BRCA2 (mutBRCA2) encoded by *BRCA2*^*9000insA*^.(C) IP-western analysis with BRCA2 (Ab-1) antibody showing interaction with phosphorylated forms of RNAPII in EUFA423 B2 and EUFA423 cells.(D) Reciprocal IP-western analysis with RNAPII antibody (601) showing interaction with BRCA2 and mutBRCA2. Inputs represent 10% of the total cell lysates.Asterisk (^∗^) denotes a nonspecific band.

BRCA2 Inactivation Diminishes PAF1 Recruitment at PPP Sites {#sec2.4}
-----------------------------------------------------------

The regulated release of RNAPII from PPP sites requires the recruitment of PAF1 ([@bib9], [@bib42]). Strikingly, ChIP analysis of PAF1 after BRCA2 depletion ([Figure 5](#fig5){ref-type="fig"}A) demonstrates reduced recruitment at both the PPP sites and across the transcription units of the actively transcribed *ACTB* and *GAPDH* genes in comparison with controls. A similar pattern of reduced PAF1 recruitment also occurs in *BRCA2*-deficient EUFA423 cells when compared with EUFA423 B2 control cells complemented with full-length BRCA2 in not only *ACTB* and *GAPDH* ([Figure 5](#fig5){ref-type="fig"}B) but also *TEFM*, *CALM3*, *VCL*, *RPL13A*, and *MRPL21* ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3E), implicating the C-terminal region of BRCA2 spanning residues 3,254--3,418 that is absent from the truncated proteins encoded by the *BRCA2*^*7691insAT\ /\ 9000insA*^ alleles in this process.Figure 5BRCA2 Inactivation Diminishes PAF1 Recruitment at PPP Sites and Subsequent H2B K120 Ubiquitination(A and B) ChIP analyses with PAF1 antibody of the *ACTB* and *GAPDH* genes in HeLa Kyoto cells 72 hr after transfection with siCtrl or siBRCA2 (A) and EUFA423 B2 and EUFA423 cells (B).(C and D) ChIP analyses with H2B K120ub antibody of *GAPDH* gene in HeLa Kyoto cells 72 hr after transfection with siCtrl or siBRCA2 cells (C) and EUFA423 B2 and EUFA423 cells (D). Fold change relative to the IgG isotype control antibody control is plotted.Plots show the mean ± SEM from three independent experiments. Data were normalized to input (2%). The 2-way ANOVA test was performed for all pairwise comparisons to determine statistical significance. Statistically significant differences are indicated (^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001).

BRCA2 Inactivation Decreases Histone H2B Ubiquitination {#sec2.5}
-------------------------------------------------------

PAF1 recruitment to RNAPII at PPP sites in turn normally conscripts the RNF20/40 E3 ubiquitin ligase complex, which triggers nucleosome disassembly by ubiquitinating histone H2B on Lys (K)120, an alteration thought to facilitate transcription elongation by opening chromatin structure downstream of the active RNAPII holoenzyme ([@bib37], [@bib39], [@bib40]). The decreased recruitment of PAF1 to the *GAPDH* gene following *BRCA2* inactivation is accompanied by diminished histone H2B K120 ubiquitination detected by ChIP in both BRCA2-depleted cells (compared to controls) ([Figure 5](#fig5){ref-type="fig"}C) and EUFA423 cells (compared to EUFA423 B2 controls) ([Figure 5](#fig5){ref-type="fig"}D). Moreover, decreased PAF1 recruitment to RNAPII and reduced histone H2B K120 ubiquitination after BRCA2 depletion are associated with an overall reproducible and quantifiable decrease in the incorporation of 5-ethynyl uridine (EU) into nascent RNA detected by immunofluorescence staining ([Figure S4](#mmc1){ref-type="supplementary-material"}), suggesting that transcription elongation is attenuated across the transcriptome.

PAF1 Overexpression Ameliorates R-Loop Accrual following BRCA2 Deficiency {#sec2.6}
-------------------------------------------------------------------------

These observations prompted us to test whether reduced PAF1 recruitment to RNAPII is a mechanism causing R-loop accrual at PPP sites in *BRCA2*-deficient cells. Indeed, depletion of PAF1 ([Figure S1](#mmc1){ref-type="supplementary-material"}B) triggers R-loop accumulation at PPP sites of *GAPDH* detected by DRIP analysis, phenocopying the pattern induced by BRCA2 depletion ([Figure 6](#fig6){ref-type="fig"}A). Combined depletion of both BRCA2 and PAF1 ([Figure S1](#mmc1){ref-type="supplementary-material"}B) does not significantly enhance this phenotype ([Figure 6](#fig6){ref-type="fig"}A), indicating that they are epistatic to one another and may thus operate via a common pathway. R-loop detection in these experiments is markedly reduced by RNase H ([Figure 6](#fig6){ref-type="fig"}A), validating its specificity. Conversely, overexpression of PAF1 in *BRCA2*-deficient EUFA423 cells ([Figure 6](#fig6){ref-type="fig"}B) ameliorates R-loop accumulation at PPP sites of *GAPDH* to a level resembling EUFA423 B2 controls ([Figure 6](#fig6){ref-type="fig"}C). Thus collectively, our results suggest that R-loop accrual at PPP sites of actively transcribed genes after BRCA2 inactivation is mediated by the reduced recruitment of PAF1 to paused RNAPII.Figure 6PAF1 Depletion Phenocopies, while PAF1 Overexpression Ameliorates, R-Loop Accumulation following BRCA2 Inactivation(A) DRIP analysis with S9.6 antibody of *GAPDH* gene in HeLa Kyoto cells transfected with indicated siRNAs for 72 hr. R-loop dissolution by RNase H enzyme is shown as a control. Plots show the mean ± SEM from three independent experiments. The 2-way ANOVA test was performed for all pairwise comparisons to determine statistical significance. Statistically significant differences are indicated (^∗^p \< 0.05 and ^∗∗^p \< 0.01).(B) Western blot analysis of the overexpression of PAF1 in EUFA423 B2 and EUFA423 cells transfected with either 5 μg (lanes 3 and 7) or 10 μg (lanes 4 and 8) of the PAF1 construct. Cell lysates were analyzed 24 hr after transfection. Bars indicate the relative positions of the wild-type and truncated forms of BRCA2 (mutBRCA2).(C) DRIP analysis of *GAPDH* gene (as in A) showing R-loop reduction after PAF1 overexpression for 24 hr in EUFA423 cells compared to untransfected EUFA423 or EUFA423 B2 controls. Plots show the mean ± SEM from three independent experiments. The 2-way ANOVA test was performed for all pairwise comparisons to determine statistical significance. Statistically significant differences are indicated (^∗^p \< 0.05; ns, not significant).(D) Schematic model depicting that BRCA2 regulates transcription elongation by RNA polymerase II to prevent R-loop accumulation. Normally, BRCA2 augments the recruitment of PAF1 to RNAPII paused at PPP sites located ∼20--60 nt from transcription start sites (arrow), fostering the switch to productive transcription elongation (left). This function is subverted by cancer-causing *BRCA2* mutations (right), diminishing PAF1 recruitment. Consequently, RNAPII accumulates at PPP sites, triggering the site-specific accrual of unscheduled R-loops, which are cleaved by the ERCC4 endonuclease to generate DNA breaks, triggering genomic instability and carcinogenesis following BRCA2 inactivation.

Discussion {#sec3}
==========

Our work suggests a model ([Figure 6](#fig6){ref-type="fig"}D) in which BRCA2 interacts with the RNAPII holoenzyme to regulate transcription elongation by augmenting the recruitment of PAF1 to the PPP sites of actively transcribed genes. BRCA2 inactivation diminishes PAF1 recruitment and may consequently reduce downstream chromatin disassembly that usually facilitates transcription elongation. These abnormalities cause RNAPII to accumulate at PPP sites, accompanied by the site-specific accrual of unscheduled R-loops that consequently lead to DNA breaks, via cleavage by the ERCC4 endonuclease ([@bib35]). Our findings suggest that R-loop formation and cleavage into DNA breaks may occur at multiple loci, raising the possibility that the mechanism we report here is a major source of genome damage following *BRCA2* inactivation.

Our model provides a mechanism for the observation that unscheduled R-loops accumulate after BRCA2 depletion ([@bib4]), which has attracted much topical attention because of the established links between R-loop accrual and genomic instability ([@bib3], [@bib13]). Indeed, we recently found that the structural chromosomal aberrations typical of BRCA2 deficiency, including radial chromosomes thought to signify aberrations in DNA repair by homologous recombination, are reduced by the overexpression of RNase H1 ([@bib36]). When taken together with these findings, the work we report here speaks to the notion that unscheduled R-loop formation caused by defective transcription elongation is an underlying cause of genomic instability after BRCA2 inactivation. Indeed, we show here that cancer-causing *BRCA2* mutations are sufficient to trigger such defects in the patient-derived EUFA423 cell line.

A small fraction of intracellular BRCA2 binds physically with BRCA1 ([@bib8]), consistent with evidence that these tumor-suppressor proteins share at least certain biological functions during the cellular response to DNA damage (reviewed in [@bib38]). However, the distribution and mechanism of R-loop accrual that we observe following BRCA2 inactivation appear to differ from that induced by depletion of BRCA1 or SETX. Our findings are consistent with prior reports ([@bib14], [@bib43]) in which siRNA-mediated BRCA1 depletion causes the accumulation of R-loops at 3′ sequences associated with the termination of transcription rather than at PPP sites. Consistent with these observations, such 3′ sites are enriched for mutations detected by next-generation sequencing in the genomes of BRCA1-deficient cancers ([@bib14]). Puzzlingly, however, it has also been recently reported ([@bib43]) that R-loops accumulate at PPP sites in the mammary luminal epithelial cells of human *BRCA1* mutation carriers and that genetic ablation of NELF-B, a subunit of the negative elongation factor complex implicated in RNAPII pausing ([@bib23], [@bib41]) that interacts with BRCA1, reduces mammary tumorigenesis in a genetically engineered murine model of *Brca1* deficiency ([@bib22]). Thus, while the mechanisms responsible for R-loop accrual after BRCA1 inactivation remain unclear, we identify here a distinct function for BRCA2 in regulating transcription elongation by augmenting PAF1 recruitment to RNAPII at PPP sites.

Notably, cancer-associated truncating mutations that delete a C-terminal region of the BRCA2 protein retain RNAPII interaction but nevertheless diminish PAF1 recruitment to increase RNAPII accumulation and R-loop accrual at PPP sites. The C-terminal region of BRCA2 apparently necessary for PAF1 recruitment is often deleted in truncating mutations associated with breast and ovarian cancer ([@bib26]), suggesting its functional significance in tumor suppression. Thus, an unrecognized function of BRCA2 in regulating transcription elongation is subverted by cancer-causing mutations, in turn provoking the site-specific accumulation of genome-destabilizing R-loops, which can be cleaved by the ERCC4 endonuclease into DNA breaks. Our work suggests that unforeseen defects in transcription elongation---besides previously reported anomalies in DNA repair, replication, or mitosis---underlie the origins of genome instability and the pathogenesis of cancers in *BRCA2* mutation carriers.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

HeLa Kyoto ([@bib2]), EUFA423 ([@bib16]), and EUFA423 B2 (stably transfected cell line with FLAG-BRCA2) ([@bib15]) cell lines were used in this study. HeLa Kyoto and EUFA423 cells were maintained in culture in DMEM containing 10% fetal bovine serum (FBS), 1% penicillin/streptomycin; for EUFA423 B2, G418 (0.75 mg/mL) was added to the medium.

Cell Lysates, Immunoprecipitation, and Western Blotting {#sec4.2}
-------------------------------------------------------

Total cell lysates (TCLs) were prepared from HeLa Kyoto, EUFA423, and EUFA423 B2 cells using NP40 lysis buffer ([@bib15]) supplemented with NaCl (final concentration, 500 mM) and Benzonase (350 μ/mL).

Immunoprecipitations (IPs) were performed using TCLs (0.25--0.5 mg) that were precleared with immunoglobulin G (IgG) and protein A/G beads prior to incubation with either BRCA2 (Ab-1) or RNAPII antibody (N20 or 601) overnight at 4°C. IPs were collected after incubation with Protein A/G Dynabeads and washed extensively with Tris buffered saline-0.1% Tween20 (TBST) and Tris-buffered saline (TBS). The IP targets were identified by western blotting on 4%--12% Bis-Tris/2-(N-morpholino)ethanesulfonic acid (BT/MES) SDS-PAGE/transfer overnight on polyvinylidene fluoride (PVDF) Immobilon membranes, blocking/primary antibody (overnight 4°C)/secondary antibody in TBST/5% milk and enhanced chemiluminescence (ECL)/ECL prime chemiluminescence detection.

Antibodies {#sec4.3}
----------

Antibodies used in this study are listed in [Table S1](#mmc1){ref-type="supplementary-material"}.

S9.6 antibody, used to detect RNA-DNA hybrids, was purified from the mouse hybridoma cell line S9.6 (ATCC- HB8730). Briefly, cell cultures were grown for ∼7 days before supernatants were centrifuged at 1,500 × *g* for 10 minutes and 0.45-μm filter sterilized. Fractions containing high concentrations of antibody were dialyzed in 2 L PBS 1× overnight followed by a second dialysis in 500 mL PBS 1×/ 50% glycerol for at least 5 hr using an ÄKTA Avant purifier (GE Healthcare). The antibody was then diluted to a final concentration of 1 μg/μL and stored at −80°C.

Plasmid Transfection {#sec4.4}
--------------------

JetPRIME transfection reagent from Polyplus was used according to manufacturer's instructions for transfecting per 15cm dish 5 or 10 μg pcDNA3_PAF1 (a gift from Dr. Matthew Meyerson, Dana-Farber Cancer Institute, Boston, MA, USA; Addgene plasmid 11059) ([@bib28]) as indicated.

siRNA Transfection {#sec4.5}
------------------

siRNAs were transfected using a standard calcium phosphate transfection protocol ([@bib20]). siRNAs used were Negative Control siRNA (1027310, QIAGEN), human BRCA2 (ON-TARGET plus SMARTpool, L-003462-00, Dharmacon), human BRCA1 (5′-GGAACCUGUCUCCACAAAG-3′), human ERCC4 (ON-TARGET plus SMARTpool, L-019946-00-0005, Dharmacon), and human PAF1 (ON-TARGET plus SMARTpool, M-020349-01, Dharmacon).

ChIP {#sec4.6}
----

ChIP was performed as described previously ([@bib14]). Briefly, cells were crosslinked in DMEM containing 1% formaldehyde (Sigma, F8775) at room temperature for 10 min with rotation. The crosslinking reaction was stopped by adding glycine (Sigma, G8898) to a final concentration of 0.125 M for 5 min at room temperature. After two washes with PBS, cells were collected in 5 mL PBS and centrifuged at 1,500 rpm for 5 min. Cell pellets were lysed in 5 mM EDTA, 50 mM Tris-HCl (pH 8.0), and 1% SDS supplemented with protease and phosphatase inhibitors. Total cell lysates were sonicated (Bioruptor, Diagenode) to obtain chromatin fragments of an average length of 200--800 bp and then centrifuged at 10,000 rpm for 10 min at 4°C. 10 μg chromatin was diluted 10-fold with 5 mM EDTA, 50 mM Tris-HCl (pH 8.0), 0.5% NP-40, and 200 mM NaCl supplemented with protease and phosphatase inhibitors. Chromatin extracts were precleared with protein G Dynabeads (Thermo Fisher) for 40 min. The precleared chromatin was incubated overnight with gentle rotation with antibodies or control antibody. The following day, antibodies were captured by adding 20uL of beads and incubated at 4°C with rotation for 2 hr. Immunoprecipitates were washed with: 1×: 20 mM Tris-HCl (pH 8), 2 mM EDTA, 0.1% SDS, 1% Triton X-100, and 165 mM NaCl; 1×: 20 mM Tris-HCl (pH 8), 2 mM EDTA, 0.1% SDS, 1% Triton X-100, and 500 mM NaCl; 1×: 10 mM Tris-HCl (pH 8), 1 mM EDTA, 1% NP-40, 1% Na-deoxycholate, and 250 mM LiCl; 1×: 50 mM HEPES (pH 7.6), 1 mM EDTA, 1% NP-40, 0.7% Na-deoxycholate, and 500 mM LiCl; 2× with Tris-EDTA (TE) (10 mM Tris-HCl \[pH7.5\] and 1 mM EDTA). After the final wash, DNA was eluted with 150 μL of 0.1 M sodium carbonate, 1% SDS at 65°C for 30 min with 1,200 rpm agitation. To reverse crosslink, 6 μL of 5 M NaCl and 2 μL proteinase K (20 mg/mL) were added and incubated at 65°C with gentle agitation for at least 3 hr. DNA was purified using a PCR purification kit (QIAGEN) and analyzed by qPCR using SYBR green mix (Roche) with the primers of interest. For γH2AX ChIP, the values were normalized to EUFA423 B2.

DRIP {#sec4.7}
----

Genomic DNA, extracted with a previously described phenol/chloroform procedure ([@bib4], [@bib12]), was digested at 37°C with a cocktail of restriction enzymes (20 U/L EcoRI, 20 U HindIII, 20 U XbaI, 25 U SSPI, and 10 U BsrGI per 50μg DNA) in buffer 2.1 (NEB) with or without RNase H (5 U/μL, NEB). Following a second DNA purification step with standard phenol/chloroform procedure, 10 μg of digested DNA was diluted in 900 μL of TE buffer (5 mM EDTA and 50 mM Tris HCl \[pH 8\]) and 100 μL of 10X DRIP buffer (100 mM NaH~2~PO~4~, 1.4 M NaCl, and 0.5% Triton-X) was added. Chromatin was precleared with 20 μL protein G Dynabeads for 40 min at 4°C. Then, 10 μg S9.6 antibody was added to the supernatant and incubated at 4°C overnight with gentle rotation. Antibody capture was done with 20 μL beads and incubation at 4°C for 2 hr. Immunoprecipitates were washed twice with 1× DRIP buffer, and once in 1× DRIP buffer + 330 mM NaCl. After the last wash, DNA was eluted by adding DRIP elution buffer (50 mM Tris-HCl \[pH 8\], 10 mM EDTA, and 0.5% SDS) and incubated at 65°C for 45 min. DNA was finally purified using PCR purification kit (QIAGEN) and analyzed by qPCR with SYBR green mix (Roche).

Primers {#sec4.8}
-------

Primers used in this study are listed in [Table S2](#mmc1){ref-type="supplementary-material"}.

Immunofluorescence for R-Loop Detection {#sec4.9}
---------------------------------------

The appropriate number of cells was plated on coverslips the day before transfection and after transfection fixed in cold methanol for 10 min at −20°C, followed by incubation for 1 min in cold acetone at room temperature. The coverslips were then quickly washed in saline sodium citrate (SSC) 4× buffer thrice and then incubated for 30 min in SSC 4×, 3% BSA to prevent nonspecific interaction. Primary antibodies were incubated overnight at 4°C (S9.6 1/100, purified in house). After three washes with PBS-tween 0.05%, coverslips were incubated at room temperature with secondary antibodies Alexa 488 and Alexa Fluor 568 (Molecular Probes, 1/500). Coverslips were mounted with DAKO mounting medium (S3023) supplemented with DAPI (1.5 μg/mL, D9542, Sigma) after three additional washes with PBS-tween 0.05%. Stained cells were imaged on a Zeiss 880 confocal microscope. Maximum projections of the z stacks of each field were analyzed using Fiji software (<https://fiji.sc/>). Intensity was calculated using a DAPI mask.

EU Incorporation and IF {#sec4.10}
-----------------------

Cells were treated with a modified nucleotide (EU; E10345) at 2 mM concentration for 30 min prior to fixation ([@bib17]) and detection with the Click-iT RNA Alexa Fluor 594 Imaging Kit (C10330, Thermo Fisher) according to the manufacturer's instructions. Image acquisition and analysis were performed as described above.

Statistical Analysis {#sec4.11}
--------------------

Statistical significance was determined using a two-tailed Student's t test for testing significance between two groups. For ChIP and DRIP analysis, statistical significances were performed using two-way analysis of variance (2-way ANOVA) followed by a Bonferroni correction. All pairwise comparisons were tested, but only statistically significant differences are indicated with asterisks in the figures. All tests were performed using GraphPad Prism 5.0. See [Table S3](#mmc1){ref-type="supplementary-material"} for more information.
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========================
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